Načítá se...
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to standard treatments, such as docetaxel and enzalutamide. Histone deacetylase (HDAC) inhibitors showed promising results in hematological malignancies, but they failed in solid tumors s...
Uloženo v:
| Vydáno v: | Biomedicines |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168248/ https://ncbi.nlm.nih.gov/pubmed/32019149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8020022 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|